Simbrinza (brinzolamide;brimonidine tartrate)
- Region
- 🇪🇺 EU
- Active substance
- brinzolamide;brimonidine tartrate
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Ocular Hypertension; Glaucoma, Open-Angle
- CHMP opinion
- Thu 22 May 2014
- EU approval
- Fri 18 Jul 2014
- Application
- EMEA/H/C/003698
- ATC
- S01EC54
- Official record
- www.ema.europa.eu
Indication
Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.
Regulatory milestones
No milestones recorded in the last year.
Follow Simbrinza
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.